Foamix Pharmaceuticals (Foamix Pharmaceuticals) Quality Rank

View and export this data going back to 2014. Start your Free Trial

What is Foamix Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Foamix Pharmaceuticals Quality Rank Related Terms

Thank you for viewing the detailed overview of Foamix Pharmaceuticals's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foamix Pharmaceuticals Ltd (NAS:FOMX) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Holzman Street, Weizmann Science Park, Rehovot, ISR, 7670402

Website

https://www.foamix.com

Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.

Executives

Ilan Hadar	officer: CFO & Country Manager	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Stanley Hirsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anna Kazanchyan	director	933 MAMARONECK AVENUE, SUITE 103, MAMARONECK NY 10543
Anthony D Bruno	director	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Stern	director	C/O THCG, INC, 650 MADISON AVENUE, 21ST FL, NEW YORK NY 10022
Rex Bright	director	5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart	officer: Chief Scientific Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski	director, officer: CEO	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Mutya Harsch	officer: CLO and General Counsel	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley	officer: Chief Commercial Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003